Close Menu

NEW YORK — German bioinformatics firm Noscendo has signed an agreement to collaborate with the University Hospital Bonn to characterize antibiotic-resistant pathogens using its Disqver next-generation sequencing-based diagnostic platform, the partners said on Monday.

Noscendo's Disqver is designed to analyze sequenced cell-free DNA from patient blood samples against a database of over 6,000 pathogens in order to detect bacteria, fungi, DNA viruses, and parasites, according to the company.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by
LGC SeraCare Life Sciences

Non-invasive prenatal testing (NIPT) continues to expand globally to support maternal-fetal patient care. 

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.